Clinical trials: Melanoma of Skin
Melanoma, Advanced Melanoma
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
CMP-001-011 is a Phase 2/3 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV) compared to nivolumab monotherapy administered to participants with unresectable or metastatic melanoma.
- Conditions
- Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma
- Trial name
- NCT04695977
- Testing
- CMP-001, Nivolumab
- Where
- 20 sites in United States
- Volunteers
- 20 people
- Sponsor
- Regeneron Pharmaceuticals
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Sarcoma, Osteosarcoma
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Background GD2 is a well-characterized tumor antigen in neuroblastoma, which is also expressed on osteosarcomas and some other sarcomas.
- Conditions
- Sarcoma, Osteosarcoma, Neuroblastoma, Melanoma
- Trial name
- NCT02107963
- Testing
- Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery
RATIONALE: Pegylated arginine deiminase may stop the growth of tumor cells by taking away an amino acid needed for cell growth. PURPOSE: This phase II trial is studying how well pegylated arginine deiminase works in treating…
- Trial name
- NCT00450372
- Testing
- ADI-PEG-20, Pharmacology Studies
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Miami
Melanoma
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
This study will examine the effectiveness and safety of glembatumumab vedotin as monotherapy or in combination with immunotherapies in patients with advanced melanoma.
- Trial name
- NCT02302339
- Testing
- glembatumumab vedotin, glembatumumab vedotin and varlilumab, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
- Where
- 14 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Melanoma
Vaccination Plus Ontak in Patients With Metastatic Melanoma
The purpose of this study is to determine if an experimental melanoma vaccine can produce an immune response in patients with metastatic melanoma, and if combining this vaccine with the drug Ontak can improve these immune…
- Trial name
- NCT00515528
- Testing
- 4-peptide melanoma vaccine, Ontak
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Chicago
Malignant Melanoma
Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients
vaccination protocol to induce specific immune responses against melanoma associated antigens by intradermal injections of mRNA coding for the corresponding antigen
- Trial name
- NCT00204607
- Testing
- mRNA, GM-CSF s.c.
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Tuebingen
Melanoma
Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus lenvatinib in patients with melanoma liver metastasis.
- Trial name
- NCT05406466
- Testing
- Tislelizumab, Lenvatinib, Cryoablation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Melanoma (Skin)
Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma
RATIONALE: Boron neutron capture therapy may selectively kill tumor cells without harming normal tissue. PURPOSE: Phase I trial to study the effectiveness of boron neuron capture therapy in treating patients with stage III…
- Trial name
- NCT00002781
- Testing
- boronophenylalanine-fructose complex
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Beth Israel Deaconess Medical Center
Melanoma, Melanoma Stage III
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
The main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for…
- Conditions
- Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin)
- Trial name
- PIVOT-12 (NCT04410445)
- Testing
- Bempegaldesleukin, Nivolumab
- Where
- 212 sites in United States, Australia and 15 more
- Volunteers
- 765 people
- Sponsor
- Nektar Therapeutics
Metastatic Melanoma, Recurrent Cutaneous Melanoma
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
This phase II trial studies how well ibrutinib works in treating patients with stage IV melanoma of the skin that has not responded to previous treatment.
- Conditions
- Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Trial name
- NCT02581930
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study
- Where
- 13 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Breast Cancer
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying…
- Conditions
- Melanoma, Breast Cancer, Renal Cell Carcinoma, Urinary Bladder Cancer
- Trial name
- Serpentine (NCT05621837)
- Testing
- MDSC quantification
- Where
- Italy
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Melanoma
A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma
A Phase Ib/IIa, multicentre, open label, dose-escalation study to evaluate the safety, tolerability, and preliminary effectiveness of intratumoural tigilanol tiglate in combination with intravenous pembrolizumab in adult patients…
- Trial name
- NCT04834973
- Testing
- tigilanol tiglate, pembrolizumab
- Where
- 2 sites in Australia
- Volunteers
- 3 people
- Sponsor
- QBiotics Group Limited
Melanoma Stage III, Melanoma
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
Subjects with resectable melanoma will receive neoadjuvant nivolumab followed by surgical resection. Post-operatively, subjects will receive open-label treatment with up to 1 year of adjuvant nivolumab or ipilimumab plus…
- Trial name
- NCT04013854
- Testing
- nivolumab, Ipilimumab
- Where
- 3 sites in United States
- Volunteers
- 67 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Melanoma, Dysplastic Nevi
Family Study of Melanoma in Italy
During the course of a case-control study of melanoma conducted at the Bufalini Hospital, Cesena, Italy in the years 1994-1996, 20 families with 2 or 3 melanoma cases were identified and studied.
- Conditions
- Melanoma, Dysplastic Nevi, Melanocytic Nevi
- Trial name
- NCT00339222
- Where
- 7 sites in Italy, Spain
- Volunteers
- 1,708 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin), Melanoma Stage IIIb-IVM1a
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
This study will investigate whether the use of talimogene laherparepvec (T-VEC) in combination with BRAF/MEK inhibitor will result in durable regional and distant recurrence free survival in the neoadjuvant setting for treatment…
- Conditions
- Melanoma (Skin), Melanoma Stage IIIb-IVM1a, Metastasis Skin, Tumor Skin
- Trial name
- NCT03972046
- Testing
- Talimogene laherparepvec (T-Vec), Dabrafenib (BRAF Inhibitor), Trametinib (MEK Inhibitor)
- Where
- United States
- Sponsor
- TriHealth Inc.
Metastatic Melanoma
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
This is a research study to evaluate treatment of metastatic melanoma patients with a combination of drugs. The combination being studied is vemurafenib (also known as Zelboraf®) and High Dose Interleukin-2 (abbreviated as HD…
- Trial name
- PROCLIVITY01 (NCT01683188)
- Testing
- vemurafenib + HD IL-2
- Where
- 21 sites in United States
- Volunteers
- 53 people
- Sponsor
- Clinigen, Inc.
Metastatic Melanoma, Metastatic Kidney Cancer
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
Background: Natural killer (NK) cells are large lymphocytes (a type of white blood cell) that are important in the immune response to cancer.
- Trial name
- NCT00328861
- Testing
- Natural Killer (NK) Lymphocytes, IL-2, Cyclophosphamide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Stage IV Melanoma, Stage III Melanoma
Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma
The purpose of this study is to determine the safety, tolerability and recommended phase 2 dose of a new drug, known as IMP321, in combination with pembrolizumab when given to patients with unresectable or metastatic melanoma.
- Trial name
- TACTI-mel (NCT02676869)
- Testing
- IMP321 (eftilagimod alpha), Pembrolizumab
- Where
- 7 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Immutep Australia Pty. Ltd.
Intraocular Melanoma, Melanoma (Skin)
Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating patients who have…
- Trial name
- NCT00003802
- Testing
- pyrazoloacridine
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.